First-In-Human Study of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
-
StatusAccepting Candidates
-
Age18 Years - 75 Years
-
SexesAll
-
Healthy VolunteersNo
Objective
This study is an international, multi-center, study of Pompe disease patients that are currently receiving enzyme-replacement therapy (ERT). The purpose of this study is to find out if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
Description
This is an open-label, fixed-sequence, ascending-dose, first-in-human study to evaluate the effect of a highly targeted rhGAA (ATB200) co-administered with a chaperone (AT2221).
The study aims to evaluate safety, tolerability, pharmacodynamics (PD), and immunogenicity of ATB200 co-administered with AT2221. The study will be conducted in 3 stages.
In Stage 1, safety, tolerability, and PK will be evaluated following sequential single ascending doses of intravenously infused ATB200.
In Stage 2, safety, tolerability, and PK will be evaluated following single* and multiple-ascending dose combinations of ATB200 and AT2221.
In Stage 3, long term safety and efficacy will be assessed following 24 month treatment of ATB200 co-administered with AT2221 (Miglustat)
In Stage 4, treatment period will begin at the end of Stage 3 and will continue as open label extension until commercialization, study discontinuation or subject withdrawal, with functional assessments every 6 months
No Muscle biopsies will be performed in this study.
Details
Full study title | An Open-label, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusions of ATB200 Alone and ATB200 Co-administered with Oral AT2221 in Adult Subjects with Pompe Disease who were Previously Treated with Alglucosidase alfa |
Protocol number | OCR19621 |
ClinicalTrials.gov ID | NCT02675465 |
Phase | Phase 1/Phase 2 |
Eligibility
Key Inclusion Criteria:
Male and female subjects between 18 and 75years of age, inclusive
Diagnosis of Pompe disease
Enzyme Replacement Therapy (ERT)-experienced subject (ambulatory):
Has received ERT with alglucosidase alfa for the previous 2-6 years, inclusive
Subject is currently receiving alglucosidase alfa (Myozyme/Lumizyme), at a frequency of once every other week
Must be able to walk 200-500 meters on the 6-Minute Walk Test (6MWT )
Has upright Forced Vial Capacity (FVC) 30% to 80% of predicted normal value
ERT-experienced subjects (non-ambulatory):
Has received ERT with alglucosidase alfa (Myozyme/Lumizyme) for ≥2 years
Is wheelchair-bound
ERT-naïve subjects (ambulatory):
Must be able to walk 200-500 meters on the 6MWT
Has upright FVC must be 30% to 80% of predicted normal value
Subject has never received alglucosidase alfa
Enzyme Replacement Therapy (ERT)-experienced subject (ambulatory):
Has received ERT with alglucosidase alfa for >7years, inclusive
Subject is currently receiving alglucosidase alfa (Myozyme/Lumizyme), at a frequency of once every other week
Must be able to walk 200-500 meters on the 6-Minute Walk Test (6MWT )
Has upright Forced Vial Capacity (FVC) 30% to 80% of predicted normal value
Exclusion Criteria:
Subject has received treatment with prohibited medications within 30 days of Baseline Visit
Subject, if female, is pregnant or breastfeeding at screening
Subject, whether male or female, planning to conceive a child during the study
Subject has a medical or any other extenuating condition or circumstance that may, in opinion of investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements
Subject has a history of allergy or sensitivity to miglustat or other iminosugars
Subjects with active systemic autoimmune disease such as lupus, scleroderma, or rheumatoid arthritis. All subjects with autoimmune disease must be discussed with the Amicus Medical Monitor
Subjects with active bronchial asthma. All subjects with bronchial asthma must be discussed with the Amicus Medical Monitor
Lead researcher
-
Barry J Byrne, MD, PhDPediatric Cardiologist
Participate in a study
Here are some general steps to consider when participating in a research study:
-
Step1
Contact the research team
Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.
Primary contact
Barry Byrne -
Step2
Get screened to confirm eligibility
You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.
-
Step3
Provide your consent to participate
If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.
-
Step4
Participate
If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.